The ophthalmic treatment track has begun, and domestic and foreign pharmaceutical companies are competing for layout

【Pharmaceutical Network Industry News】With the intensification of population aging and the increase in the use of electronic products, age-related eye diseases, metabolism-related eye diseases and fundus lesions caused by high myopia are increasing
.
It is understood that in order to meet the needs of the vast and continuous ophthalmic treatment market, many companies are currently increasing their layout in this field
.
Recently, Aier Ophthalmology issued an announcement that it intends to acquire 70% of the equity of Xinzhou Aier Eye Hospital Co.
, Ltd.
("Xinzhou Aier") held by Tianjin Accin Enterprise Management Partnership (Limited Partnership) ("Tianjin Connecti"); Acquired a 55% equity
interest in Yichang Xiling Aier Eye Hospital Co.
, Ltd.
("Xiling Aier") held by Hunan Liangshi Changxing Medical Industry Management Partnership (Limited Partnership) ("Liangshi Changxing").
In fact, the current field of ophthalmic treatment is actually attracting the participation of many pharmaceutical companies around the
world.
Among them, in recent years, large pharmaceutical companies have invested huge in this regard
.
For example, in June 2019, AbbVie acquired Aerjian for US$63 billion, further enriching the ophthalmic treatment pipeline and considering it as one of its core businesses; In December 2021, Novartis acquired Gyroscope Therapeutics
, a British ophthalmic gene therapy company, for $1.
5 billion.
In China, the new generation of Biotech is also scrambling to enter the ophthalmology track
.
It is reported that at present, in addition to Oakon Weishi, Zhaoke Ophthalmology and other enterprises have successively gone to Hong Kong to list
.
In addition, in the innovative research and development of ophthalmic drugs, more and more domestic enterprises are accelerating their layout
.
For example, on September 25, Kelun Pharmaceutical announced that the chemical "brimonidine timolol eye drops" of Jiangxi Kelun Pharmaceutical Co.
, Ltd.
, a subsidiary of the company, was recently approved by
the State Drug Administration for drug registration 。 In early August, Zhaoke Ophthalmology said that its partner Vyluma Inc.
(a wholly-owned subsidiary of the American biopharmaceutical company Nevakar Inc.
) is conducting Phase III clinical trials of NVK002 (one of the core products of Zhaoke Ophthalmology) in Europe and the United States, which is expected to be completed by the end of 2022, and expects to submit a new drug application to the US Food and Drug Administration in 2023, and NVK002 is currently positioned as the world's first clinically proven approved drug to treat the deepening of myopia
。 In April, Mixing Pharmaceutical announced the introduction of two pre-research presbyopia therapeutics drugs developed by the American company LENZ Therapeutics in China with an advance payment of $110 million and a potential milestone payment
.
It is worth mentioning that in the face of a huge market, the capital market has not missed the opportunity to
nugget gold.
According to the data, since 2021, a total of 8 investment and financing transactions
have been completed in the field of domestic ophthalmic treatment.
In addition, in recent years, many investment institutions, including Sequoia China, Hillhouse Investment, Gao Tejia, Zhengxingu Capital, etc.
, have also participated in the layout
of the ophthalmic treatment field.
The industry believes that the ophthalmic treatment track has become the darling
of the capital market.
Analysts believe that in the long run, in the context of the prevention and control of myopia in adolescents will receive more and more attention from the country, and the effective control of myopia occurrence and development has gradually become a difficult task in the medical community, the ophthalmic industry will have great potential
.
At the same time, related companies are expected to usher in more opportunities
.
Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.